X4 Pharmaceuticals names Nancy Lurker as chair of board
Ms. Lurker is an experienced industry executive who has a wide-ranging background in leadership roles at a diverse range of healthcare companies and is currently a Director on the Cancer Treatment Centers of America’s Board of Directors and a member of the Novo Advisory Group.
Over the past decade, Ms. Lurker has served on the Board of Directors of several public companies including Mallinckrodt Pharmaceuticals, Auxilium Pharmaceuticals and Elan Pharmaceuticals.
She is currently President, Chief Executive Officer and a member of the Board of Directors of pSivida Corporation, a provider of miniaturized, sustained-release drug delivery products focused on the eye.
Prior to pSivida, she was President, Chief Executive Officer and Board Director for PDI, a commercial services company to the biopharmaceutical industry.
Earlier in her career Ms. Lurker served as Senior Vice President and Chief Marketing Officer for Novartis Pharmaceuticals Corporation (the U.S. subsidiary of Novartis AG).
She also served as President and Chief Executive Officer of ImpactRx, Group Vice President-Global Primary Care Products for Pharmacia Corporation, and as a member of Pharmacia’s U.S. Executive Management Committee.
Ms. Lurker received a Bachelor of Science degree in biology magna cum laude from Seattle Pacific University, and earned a Masters in Business Administration from the University of Evansville. ■
LATEST MOVES FROM Massachusetts
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
- Acer Therapeutics appoints William T. Andrews as CMO
More inside POST